Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CV Sciences, Inc. (CVSI)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0459+0.0049 (+11.95%)
At close: 03:54PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0410
Open0.0403
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0403 - 0.0490
52 Week Range0.0300 - 0.1800
Volume888,472
Avg. Volume456,806
Market Cap6.89M
Beta (5Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-0.1330
Earnings DateMar 29, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CVSI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CV SCIENCES INC
    Analyst Report: Aurora Cannabis Inc.Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • PR Newswire

    CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD™ Reserve Collection Softgels

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced the launch of their popular +PlusCBD™ Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on Thursday, Jan. 19.

  • PR Newswire

    CV Sciences, Inc. Reports Third Quarter 2022 Financial Results

    CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2022.

  • PR Newswire

    CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2022 RESULTS ON NOVEMBER 14, 2022

    CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2022, before the stock market opens on Monday, November 14, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.

Advertisement
Advertisement